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Abstract 
Introduction and objectives 
In Spain, data based on large population-based cohorts adequate to provide an accurate prediction of cardiovascular 
risk have been scarce. Thus, calibration of the EuroSCORE and Framingham scores has been proposed and done for 
our population. The aim was to develop a native risk prediction score to accurately estimate the individual 
cardiovascular risk in the Spanish population. 
Methods 
Seven Spanish population-based cohorts including middle-aged and elderly participants were assembled. There were 
11 800 people (6387 women) representing 107 915 person-years of follow-up. A total of 1214 cardiovascular events 
were identified, of which 633 were fatal. Cox regression analyses were conducted to examine the contributions of the 
different variables to the 10-year total cardiovascular risk. 
Results 
Age was the strongest cardiovascular risk factor. High systolic blood pressure, diabetes mellitus and smoking were 
strong predictive factors. The contribution of serum total cholesterol was small. Antihypertensive treatment also had a 
significant impact on cardiovascular risk, greater in men than in women. The model showed a good discriminative 
power (C-statistic = 0.789 in men and C = 0.816 in women). Ten-year risk estimations are displayed graphically in 
risk charts separately for men and women. 
Conclusions 
The ERICE is a new native cardiovascular risk score for the Spanish population derived from the background and 
contemporaneous risk of several Spanish cohorts. The ERICE score offers the direct and reliable estimation of total 
cardiovascular risk, taking in consideration the effect of diabetes mellitus and cardiovascular risk factor management. 
The ERICE score is a practical and useful tool for clinicians to estimate the total individual cardiovascular risk in 
Spain. 
Resumen 
Introducción y objetivos 
En España no existen unas cohortes poblacionales suficientemente grandes para hacer predicciones precisas del 
riesgo cardiovascular. Las ecuaciones de Framingham y EuroSCORE calibradas son las más utilizadas en España. El 
objetivo es desarrollar la primera ecuación de predicción autóctona para estimar con precisión el riesgo 
cardiovascular individual en España. 
Métodos 
Análisis conjunto de siete cohortes españolas de población de mediana edad y anciana. La población del estudio —
11.800 personas (6.387 mujeres)— aportó un total de 107.915 personas-año de seguimiento y 1.214 eventos 
cardiovasculares (633 de ellos, mortales). Se efectuó un análisis de regresión de Cox para examinar la contribución de 
los diferentes factores al riesgo de cualquier evento cardiovascular (mortal y no mortal). 
Resultados 
La edad fue el principal factor de riesgo de eventos cardiovasculares. La presión arterial sistólica, la diabetes mellitus, 
el tabaquismo y el tratamiento antihipertensivo fueron factores predictivos fuertemente asociados con el riesgo 
cardiovascular. En cambio, la contribución del colesterol total sérico fue pequeña, especialmente en los mayores de 
70 años. El modelo final de riesgo mostró un buen poder discriminatorio (estadístico C = 0,789 en varones y 
C = 0,816 en mujeres). 
Conclusiones 
ERICE es una nueva ecuación de riesgo cardiovascular genuinamente española obtenida a partir del riesgo 
concurrente individual de los participantes en varias cohortes. La ecuación ERICE ofrece una estimación directa y 
fiable del riesgo cardiovascular total teniendo en cuenta factores como la diabetes mellitus y el tratamiento 
farmacológico de los factores de riesgo cardiovascular, habitualmente no incluidos en otras ecuaciones. 
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Introduction 
Current recommendations on the prevention of cardiovascular disease (CVD) in clinical practice 
encourage health workers to assess the individual's total CVD risk rather than focus on a specific CVD 
outcome alone.1 
Several risk calculators are available in Europe and the United States2, 3, 4 and 5 but most of them have 
been only validated in middle-aged populations or in areas with a relatively high coronary heart disease 
(CHD) risk and they do not account for the effect of medications used for risk factor management.6, 7 and 8 
Although calibration of these foreign scores have been done in countries with lower CHD rates such as 
China and Spain and validated in the VERIFICA Study8. However, until now we did not have a native 
scale of cardiovascular risk based on the follow-up of large cohorts and derived from the same population 
where it will be later administered. In most of the Southern European countries, however, no sufficiently 
large population-based cohorts existed thus far to provide accurate and reliable estimates of the CVD risk 
by age and sex9. Furthermore, the impact of diabetes mellitus (DM) that is an important aspect to be 
considered in the CVD risk assessments has not been included in the available European risk scores 
leaving out the potential impact of DM when assessing CVD risk in clinical practice.2 
The existing risk scores vary widely in terms of the background risk in study populations, predictors 
and outcomes considered (the Framingham score focuses on the CHD incidence and the SCORE 
(Systematic COronary Risk Evaluation) function on CVD mortality rather than the total CVD risk). Most 
can be used up to the age of 75 years. The scores do not take into account the possible effects of 
pharmacological risk factor management in the study population and will therefore underestimate the 
actual cardiovascular risk. The SCORE function does not include DM as a risk factor, and the 
Framingham algorithm underestimates its impact. 
In addition, most of the existing scores were derived from cohorts of primarily middle-aged people at 
baseline, leaving older persons underrepresented. For example, the SCORE function concentrates on 
middle-aged people and is only recommended for use in the age range of 40 to 65 years.4 The estimation 
of cardiovascular risk in people > 70 years is problematic because the predictive power of classical CVD 
risk factors decreases with age. For instance, the Framingham score seems to be of limited utility for 
elderly people, according to the Leiden 85-plus study, which showed a very poor discrimination, with the 
area under the curve in the receiver operating characteristics calculation only 0.53 (95% confidence 
interval [95%CI], 0.43-0.64)7 
According to the guidelines of the Fourth Joint Task Force,2 it is important to develop a European 
CVD risk score adapted to specific geographical areas and to include individuals at older ages that will 
allow a more precise identification of asymptomatic individuals at high risk of CVD and a more effective 
implementation of the preventive interventions targeted to lower the total CVD risk. Hence, there is a 
place for a new CVD score that overcomes some of the limitations of previous tools. 
The aim of this study is to develop a new CVD risk assessment tool that will accurately predict the 
individual risk of total CVD in the population of Spain.  
Methods 
Data Sources 
The ERICE (Ecuación de Riesgo Cardiovascular Española) project comprised seven population-based 
cohort studies in different geographical areas of Spain. The designs of the original studies have been 
detailed elsewhere. 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20 A collaborative database was created with the individual 
data from all participants in these 7 cohorts ( Table 1). 
Table 1. Characteristics of the Cohorts Included in the ERICE Project 
Study Location Study population, no. 
Age, mean (SD) [age 
range at baseline, y] 
Year of recruitment, 
follow-up, mean 
(SD), y 
Follow up, 
person-
years 
Number of 
cases lost to 
follow-up 
  Men Women Total     
         
EPICARDIAN11 and 12 
Madrid, Lugo, Avila 
(center, northwest) 
1463 2015 3478 74 (6.8) [> 65] 1994 (8.0 [3.0]) 27 789 2 (0.1) 
VIVA13 and 14 
Lugo, Barcelona 
(northwest, northeast) 
365 374 739 48.9 (9.1) [35-64] 1996 (9.4 [1.2]) 6963 33 (4.5) 
REGICOR17 Girona (northeast) 765 846 1611 52.4 (12.7) [30-74] 
1994/1996 (6.7 
[1.2]) 
10 756 83 (5.2) 
CORSAIB15 Mallorca (east) 736 833 1569 53.3 (11.3) [35-74] 1999 (7.4 [1.2]) 11 549 0 (0.0) 
Talavera19 Toledo (centre) 561 627 1188 54.8 (13.3) [30-74] 1994 (9.5 [2.0]) 11 283 21 (1.8) 
Albacete18 Albacete (southeast) 450 534 984 53.1 (14.6) [> 30] 1992 (11 [2.2]) 10 834 0 (0.0) 
Murcia20 Murcia (southeast) 1073 1158 2231 44.8 (10.2) [30-65] 1991 (12,9 [2]) 28 741 245 (11.0) 
Total  5413 6387 11 800 57.6 (15.4) [> 30] (9,1 [3,1]) 107 915 384 (3.3) 
         
 
Vital status was ascertained for 100% of participants. 
Lost to follow-up was considered when there was no information about the vital status when the cohort was closed. 
Unless otherwise indicated, data are expressed as No. (%) or mean (standard deviation). 
The studies had to meet the following criteria: single or multicenter surveys of general adult 
population of both sexes aged ≥ 20 years; a clear description of the target population and the sampling 
methods, a random selection of participants, an adequate participation in the baseline survey (> 60%), a 
sufficiently long follow-up, a small number of participants lost to follow-up, a description of standardized 
measurement of clinical variables (blood pressure, blood lipids, smoking, and fasting plasma glucose) and 
a reliable method of assessing CVD events during the follow-up. In this analysis, only individuals aged 
≥ 30 years and free of clinical CVD at baseline were included. 
Measurement and Definition of Cardiovascular Risk Factors 
The CVD risk factors were assessed at baseline examination. The final common database included the 
following study variables: age, sex, place of residence, body mass index, systolic blood pressure (SBP), 
diastolic blood pressure, cigarette consumption, total serum total cholesterol (TC), fasting or random 
glucose, and personal history of hypertension, hypercholesterolemia, DM, and drug treatment for 
hypertension, hypercholesterolemia, and DM. Whole blood and capillary glucose values were converted 
to plasma values using the formula proposed by Carstensen et al.21 For the development of Cox models, 
the independent variables were categorized as follows: age was grouped in 10-year categories except for 
women < 50 years, because there were few cardiovascular events in this age- group. Systolic blood 
pressure was categorized: < 140 mmHg; 140-159 mmHg; 160-179 mmHg; ≥ 180 mmHg. Categories for 
TC were: < 5.2 mmol/L, 5.2-6.4 mmol/L, 6.5-7.7 mmol/L and ≥ 7.8 mmol/L. The smoking status was 
categorized as nonsmokers and smokers (including exsmokers who had stopped smoking < 6 months 
earlier and those who smoked at baseline). 
Hypertension was considered when SBP ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg or 
treatment with antihypertensive drugs.22 Hypercholesterolemia was considered when TC ≥ 5.1 mmol/L or 
treatment with lipid-lowering drugs.23 Diabetes mellitus was defined as fasting venous plasma glucose 
≥ 7.0 mmol/L, random capillary glucose ≥ 11.1 mmol/L or treatment with oral antidiabetic drugs or 
insulin at baseline. Body mass index was calculated for each individual using the formula of weight in 
kilograms divided by the square of height in meters, and obesity was defined as body mass index ≥ 30. 
Follow-up and Cardiovascular Events 
Information on CVD events was collected by searching all potential sources (primary care and hospital 
records, interviews with general practitioners, National Institute of Statistics, mailings, and phone calls to 
the participants or their relatives). The date and cause of death of each deceased individual in the cohort 
was also confirmed through the Spanish National Death Index and the mortality registries of each 
autonomic community. 
Cardiovascular Disease Event Registration 
Using the International Classification of Diseases (ICD-9 and ICD-10), causes of death were defined as 
CHD (ICD-9: 410-414, ICD-10: I20-I25), cerebrovascular disease (ICD-9: 430-434, 436-438; ICD-
10:I58-I61), and other potential cardiovascular conditions (ICD-9: 797-799; ICD-10: I46, R96, R98, I50). 
Cardiovascular Disease Event Classification 
Coronary events were classified following the World Health Organization MONICA Project24 algorithm 
adapted by the REGICOR.25 Cerebrovascular cases were classified following the MONICA stroke study 
algorithm.26 
Cardiovascular disease is a composite of first “hard” coronary event (definite fatal and nonfatal 
myocardial infarction and possible fatal myocardial infarction) or cerebrovascular event (including acute 
ischemic stroke and other nondetermined stroke events). 
Statistical Methods 
For the description of the selected data, arithmetic mean (standard deviation) was used when the variables 
were continuous and relative frequency distribution when categorical. For comparison of proportions, the 
Pearson chi-square test and the Sommer D were used in the case of ordinal variables. For group 
comparison, the Student-Fisher t test was used in the case of independent binary measures and analysis of 
variance for variables of more than 2 categories. 
Multivariate Models and Estimation of General Cardiovascular Disease Risk Functions 
To analyze the association between each independent variable collected (age, sex, SBP, diastolic blood 
pressure, smoking, DM, TC, serum high-density lipoprotein cholesterol, and triglycerides) and the 
outcome variables, both bivariate and multivariate analyses were performed. Due to the precise data 
available about risk factor treatments, modeling the impact of a participant's SBP or TC levels with or 
without pharmacological treatment for these two risk factors was possible. 
Cox regression analyses were conducted to identify and examine the contributions of the different 
variables for CVD as the potential basis for the ERICE-score. Coefficients independently associated with 
each potential risk factor for the first recorded CVD event were estimated separately for men and women. 
A Kaplan-Meier extrapolation of the first fatal or nonfatal CVD event during the 10-year period was 
performed to calculate the overall mean ERICE cumulative incidence of the CVD event. To estimate the 
survival function, analysis was performed using Kaplan-Meier method stratified by sex and age (≤ 70 
years or > 70 years). Cox models were also adjusted by the study cohort. Omnibus test was used to 
validate the model (P < .05). Sex-specific risk score sheets for CVD event prediction using categorical 
variables were developed from the β-coefficients of Cox proportional hazards models. 
A graphical inspection of the proportionality of the hazard assumption was carried out. Possible 
violations of the proportional hazards assumption in Cox regression were assessed using graphical 
methods. In addition, the model assumptions were tested for compliance. 
We split the ERICE score into 6 categories of total 10-year CVD risk: low risk: < 5%; mild risk: 5% 
to 9%; moderate risk: 10% to 14%; moderate-high risk: 15% to 19%; high risk: 20% to 29%, and very 
high risk: ≥ 30%.  
Ethics 
Our research is in compliance with the Helsinki Declaration. All individual studies obtained informed 
consent of the participants at baseline examination, and all studies were approved by the local ethics 
committees. 
Results 
Characteristics of the Study Population 
There were 11 800 participants (5413 men and 6387 women) representing 107 915 person-years of 
follow-up. The median follow-up for the entire study was 9.1 years. A complete follow-up was reported 
in 11 416 people (96.7% of the total population; 5235 men and 6181 women). We were able to assess the 
vital status of 100% of cohort participants (Table 1). 
Table 2 shows the cardiovascular risk factors and events distribution by sex and study cohort. In total, 
1214 CVD events occurred in the entire cohort during the 10-year follow-up period (638 in men and 576 
in women), of which 633 were CVD deaths (325 in men and 308 in women). The distribution by sex of 
the CVD risk factor categories in the ERICE study is detailed in Table 1 of supplementary material. 
Variables such as diastolic blood pressure, body mass index, and lipid-lowering medication were not 
statistically associated with CVD (Table 2 of supplementary material), and there were only some 
participants with data available for triglycerides and high-density lipoprotein cholesterol (only one third 
of the participants). 
Table 2. Risk Factor Information and Events by Sex and Study Cohort 
Study No. 
Age at 
baseline, 
mean (SD), 
y 
Smokers, 
% 
BMI, 
mean 
(SD) 
Obesity, 
% 
HDL-C, 
mean (SD), 
mmol/L 
TC, mean 
(SD), 
mmol/L 
Hypercholes-
terolemia, % 
FPG, mean 
(SD), 
mmol/L 
DM, 
% 
(SD), 
mmHg 
HT, 
% 
Total No. 
of deaths 
(all causes) 
First CV 
events (fatal 
events), No. 
Cumulative 
incidence, % 
(follow-up, mean 
[SD]), y 
                
Total men 5413 56.9 (15.2) 61.9 
27.1 
(3.8) 
20.8 1.3 (0.4) 5.5 (1.1) 18.1 5.7 (1.6) 8.8 
136.2 
(19.5) 
48.7 1107 638 (325) 11.79 (8.9 [3.2]) 
 EPICARDIAN11 and 12 1463 73.7 (6.6) 74.2 
26.9 
(3.9) 
19.1 1.2 (0.3) 5.4 (1.2) 18.2 5.9 (1.7) 10.7 
143.0 
(19.6) 
64.1 703 356 (222) 24.33 (7.5 [3.2]) 
 VIVA13 and 14 365 48.6 (9.1) 72.9 
27.1 
(3.6) 
20.3 1.2 (0.3) 5.7 (1.0) 20.5 5.6 (1.1) 5.5 
124.2 
(18.4) 
26.3 17 15 (5) 4.11 (9.3 [1.4]) 
 REGICOR17 765 52.7 (12.8) 65.3 
26.7 
(3.7) 
18.4 1.2 (0.4) 5.8 (1.1) 25.8 5.9 (1.5) 10.3 
134.0 
(19.5) 
41.6 52 33 (9) 4.31 (6.5 [1.3]) 
 CORSAIB15 736 53.3 (11.5) 36.5 
27.5 
(4.0) 
23.6 1.2 (0.3) 5.6 (1.1) 20.5 5.9 (1.8) 14.9 
136.1 
(18.8) 
50.8 74 57 (20) 7.74 (7.2 [1.5]) 
 Talavera19 561 55.3 (13.3) 36.9 
27.3 
(3.8) 
22.3 1.2 (0.3) 5.5 (1.0) 15.5 5.2 (1.7) 7.1 
137.9 
(19.4) 
47.4 92 66 (33) 11.76 (9.2 [2.3]) 
 Albacete18 450 52.1 (14.5) 67.1 
27.5 
(4.0) 
23.6 — 5.4 (1.0) 13.6 5.7 (1.6) 8.4 
133.9 
(19.3) 
47.1 67 38 (13) 8.44 (10.8 [2.4]) 
 Murcia20 1073 45.0 (10.5) 67.5 
27.2 
(3.6) 
21.0 1.5 (0.4) 5.3 (1.1) 13.3 — 3.4* 
132.5 
(17.2) 
40.1 102 73 (23) 6.80 (12.7 [2.3]) 
Total women 6387 58.1 (15.5) 15.2 
27.8 
(5.1) 
29.6 1.5 (0.4) 5.6 (1.1) 20.9 5.6 (1.7) 8.4 
136.0 
(22.5) 
50.8 875 576 (308) 9.02 (9.4 [2.9]) 
 EPICARDIAN11 and 12 2015 74.3 (6.9) 8.0 
27.7 
(5.0) 
29.4 1.3 (0.3) 5.9 (1.2) 29.9 5.9 (1.9) 12.1 
146.9 
(20.6) 
74.3 638 412 (235) 20.45 (8.4 [2.8]) 
 VIVA13 and 14 374 49.3 (9.1) 16.1 
27.1 
(4.7) 
25.4 1.5 (0.3) 5.7 (1.0) 20.3 5.2 (1.2) 3.5 
124.4 
(19.9) 
27.8 6 8 (0) 2.14 (9.5 [1.0]) 
 REGICOR17 846 52.2 (12.6) 18.7 
26.6 
(4.5) 
19.9 1.5 (0.4) 5.8 (1.1) 25.1 5.6 (1.5) 7.2 
129.7 
(20.9) 
38.4 31 16 (9) 1.89 (6.9 [1.0]) 
 CORSAIB15 833 53.3 (11.1) 19.2 
27.6 
(5.3) 
29.1 1.5 (0.3) 5.6 (1.0) 19.4 5.5 (1.5) 8.4 
131.3 
(22.2) 
43.3 29 30 (5) 3.60 (7.5 [1.0]) 
 Talavera19 627 54.3 (13.3) 12.8 
29.4 
(5.3) 
40.2 1.3 (0.3) 5.6 (1.0) 17.9 5.1 (1.7) 7.3 
135.7 
(21.9) 
45.8 61 42 (22) 6.70 (9.8 [1.7]) 
 Albacete18 534 53.9 (14.6) 16.3 
28.6 
(5.3) 
35.8 — 5.3 (0.9) 10.5 5.7 (1.9) 10.9 
137.7 
(23.4) 
51.7 47 31 (17) 5.81 (11.2 [2.0]) 
 Murcia20 1158 44.7 (10.0) 22.6 
28.1 
(4.9) 
30.1 1.7 (0.5) 5.0 (1.1) 9.7 — 4.1* 
128.3 
(19.9) 
33.9 63 37 (20) 3.20 (13.1 [1.5]) 
Total ERICE 11800 57.5 (15.4) 36.6 
27.5 
(4.6) 
25.5 1.4 (0.4) 5.5 (1.1) 19.6 5.6 (1.7) 8.6 
136.1 
(21.2) 
49.8 1982 1214 (633) 10.3 (9.1 [3.1]) 
                
 
BMI, body mass index; CV, cardiovascular; DM, diabetes mellitus; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; SBP, systolic blood pressure; SD, standard deviation; HT, hypertension; 
TC, total cholesterol. 
Hypertension: systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg or antihypertensive treatment. 
Diabetes mellitus: fasting plasma glucose > 7 mmol/L, random capillary glycaemia > 11 mmol/L or antidiabetic treatment. 
Hypercholesterolemia: total cholesterol > 6.5 mmol/L or lipid-lowering treatment. 
Obesity: body mass index > 30 kg/m2. 
Unless otherwise indicated, data are expressed as mean (standard deviation). 
*Self-reported. 
The multivariate adjusted hazard ratios (HR) of CVD for the different cardiovascular risk factors included in the final Cox 
model in men and women are shown in Table 3 and Table 4. Antihypertensive drug treatment had a significant impact, greater 
in men than in women. Elevated serum cholesterol increased the risk of acute coronary event in men (HR = 1.50; 95%CI, 1.02-
2.19) and women (HR = 3.64; 95%CI, 1.64-8.11) aged < 70 years, but at older ages the risk did not increase. Elevated serum 
cholesterol did not significantly increase the risk of cerebrovascular disease. 
Table 3. Multivariate Cox Model for a First Fatal or Nonfatal Average 10-year Cardiovascular Event. Men 
 No. (total events, no.) β SE HR 95%CI P 
Age at baseline (age groups) 
40-49 964 (25) 0.638 0.343 1.89 0.97-3.71 .063 
50-59 788 (59) 1.681 0.310 5.37 2.93-9.90 <.001 
60-69 1323 (208) 2.402 0.299 11.04 6.15-19.83 <.001 
70-79 963 (223) 2.862 0.310 17.50 9.54-32.12 <.001 
≥ 80 309 (110) 3.519 0.323 33.75 17.91-63.58 <.001 
Smokera 
Yes 3209 (428) 0.282 0.092 1.33 1.11-1.59 .002 
SBP (mmHg) 
No treated 
140-159 1141 (181) 0.407 0.107 1.50 1.22-1.85 <.001 
160-179 342 (61) 0.490 0.150 1.63 1.22-2.19 .001 
≥ 180 75 (15) 0.552 0.270 1.74 1.02-2.95 .041 
Treated 
< 140 225 (54) 0.753 0.158 2.12 1.56-2.90 <.001 
140-159 295 (67) 0.585 0.146 1.80 1.35-2.39 <.001 
160-179 187 (53) 0.850 0.160 2.34 1.71-3.20 <.001 
≥ 180 69 (22) 0.925 0.230 2.52 1.61-3.96 <.001 
Total cholesterol (mmol/L) 
5.2-6.4 2243 (275) 0.018 0.089 1.02 0.86-1.21 .835 
 6.5-7.7 764 (101) 0.068 0.119 1.07 0.85-1.35 .570 
 ≥ 7.8 131 (14) −0.041 0.276 0.96 0.56-1.65 .881 
       
 
95%CI, 95% confidence interval; HR, hazard ratio; SBP: systolic blood pressure; SE, standard error. 
Category of reference: young (men 30-39 years old; women 30-49 years old), nonsmoker, nondiabetics, nontreated with antihypertensive drugs, systolic blood 
pressure < 140 mmHg, total cholesterol < 5.2 mmol/L. 
Model was adjusted by the cohort effect. 
Harrel C-statistic = 0.792. 
a Smoker: current smoker and exsmoker (≤ 6 months). 
b Diabetic: fasting plasma glucose > 7 mmol/L or treatment with insulin or oral antidiabetic drugs at baseline.  
Table 4. Multivariate Cox Model for a First Fatal or Nonfatal Average 10-year Cardiovascular Event. Women 
 No. (total events, no.) β SE HR 95%CI P 
Age at baseline (age groups) 
50-59 908 (38) 2119 0.330 8.32 4.36-15.89 <.001 
 60-69 1494 (132) 2739 0.318 15.47 8.30-28.84 < .001 
 70-79 1245 (227) 3471 0.329 32.18 16.87-61.38 < .001 
 ≥ 80 472 (166) 4368 0.339 78.86 40.58-153.22 < .001 
Smokera 
Yes 910 (46) 0.407 0.159 1.50 1.10-2.05 .011 
Diabetic       
Yes 530 (98) 0.446 0.113 1.56 1.25-1.95 < .001 
SBP (mmHg) 
No treated 
140-159 1106 (147) 0.065 0.124 1.07 0.84-1.36 .603 
  160-179 321 (32) −0.121 0.197 0.89 0.60-1.30 .540 
  ≥ 180 79 (19) 0.449 0.248 1.57 0.96-2.55 .070 
Treated 
< 140 384 (55) 0.272 0.160 1.31 0.96-1.79 .089 
  140-159 605 (93) 0.193 0.136 1.21 0.93-1.58 .157 
  160-179 392 (68) 0.178 0.151 1.19 0.89-1.61 .241 
  ≥ 180 159 (34) 0.355 0.195 1.43 0.97-2.09 .068 
Total cholesterol (mmol/L) 
5.2-6.4 2628 (254) 0.014 0.100 1.01 0.83-1.23 .892 
 6.5-7.7 1058 (131) −0.024 0.118 0.98 0.77-1.23 .840 
 ≥ 7.8 188 (20) −0.227 0.244 0.80 0.49-1.28 .352 
       
 
95%CI, 95% confidence interval; HR, hazard ratio; SBP: systolic blood pressure; SE, standard error. 
Category of reference: young (men 30-39 years old; women 30-49 years old), nonsmoker, nondiabetics, nontreated with antihypertensive drugs systolic blood 
pressure < 140 mmHg, total cholesterol < 5.2 mmol/L. 
Model was adjusted by the cohort effect. 
Harrel C-statistic = 0.819. 
a Smoker: current smoker and exsmoker (≤ 6 months). 
b Diabetic: fasting plasma glucose > 7 mmol/L or treatment with insulin or oral antidiabetic drugs at baseline. 
The entire model showed a good discriminative power (C-statistic = 0.789 in men and C = 0.816 in women). Score sheets 
were developed to predict CVD events in men and women from the β-coefficients of Cox proportional hazard models. Figure 
1, Figure 2, Figure 3 and Figure 4 show the 10-year risk of a fatal and nonfatal CVD event in men and women with and 
without antihypertensive treatment. 
 
 
 
Figure 1. Ten-year absolute risk of a first fatal or nonfatal cardiovascular event. Men without antihypertensive treatment. DBP, diastolic blood pressure; SBP, 
systolic blood pressure. 
 
 
 
Figure 2. Ten-year absolute risk of a first fatal or nonfatal cardiovascular event. Men with antihypertensive treatment. DBP, diastolic blood pressure; SBP, 
systolic blood pressure. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Ten-year absolute risk of a first fatal or nonfatal cardiovascular event. Women without antihypertensive treatment. DBP, diastolic blood pressure; 
SBP, systolic blood pressure. 
 
 
 
Figure 4. Ten-year absolute risk of a first fatal or nonfatal cardiovascular event. Women without antihypertensive treatment. DBP, diastolic blood pressure; 
SBP, systolic blood pressure. 
  
Discussion 
The ERICE-score is unique in being based on a large cohort of 11 800 Spanish adults, covering a wide age range with uniform 
and harmonized baseline data. In contrast to previous scores such as the Framingham and EuroSCORE that were based on 
populations recruited before the 1990s, our estimates are based on more recent cohorts and offer different charts for individuals 
treated with antihypertensive drugs or not. The CVD incidence rates of this study stress the need of improving primary 
prevention measures, as more than half of the first CVD events resulted in death; the high case-fatality of coronary and stroke 
events is known also from previous studies. 
Components of the Risk Score 
Age is the strongest predictor of CVD risk in both men and women. Despite the influence of age, favorable levels of all 
modifiable CVD risk factors assure a minimal CVD risk in a Mediterranean population aged < 70 years.9 
Our results show that a completely different pattern is observed between the two sexes with regard to modifiable 
cardiovascular risk factors. In men, high SBP is the strongest predictive CVD risk factor, followed by DM and smoking with 
similar impacts. In women, DM plays a crucial role, followed by smoking and very high SBP (>180 mmHg). Antihypertensive 
drug treatment has a greater impact in men than in women. Contribution of high TC levels to the cardiovascular risk was small 
both in men and women. These results are in keeping with previous findings regarding the CVD risk in the Spanish 
population.27 Also, we confirm that it is important to derive the CVD prediction model in the same population where the risk 
score will be later administered.28 
Comparison With Previous Risk Estimates 
To date, the CVD prediction charts used to predict a CVD event in Spain have relied on risk estimates based on American 
(REGICOR)5, 29 and 30 or European (SCORE)7 and 31 populations, and the scores adapted for Spain have had important limitations 
as they came from small population samples, most of them based on occupational cohorts and geographically limited to the 
north east area of Spain.32, 33 and 34 Another important limitation of previous estimates is that they are limited to CHD risk or 
CVD deaths. By calculating total CVD risk, we provide a better estimate of overall individual risk in a European region with 
low rates of CHD, such as Spain. 
Moreover, previous estimates do not include DM at all or, as the Framingham algorithm, are based on a small number of 
DM people (4%, since diabetes at the time of the Framingham study's baseline data collection was not as common as more 
recently) and used its own definition of DM. ERICE-charts, following the recommendations of the Joint Task Force of the 
European Societies,1 include a representative number of people with DM and give separate risk charts for this risk factor. 
Finally, the ERICE-charts uniquely include cells for individuals aged 70 years to 79 years and ≥ 80 years, since the cohort 
included a large proportion of people > 75 years and accounted for the use of risk-factor-modifying drugs, which allows the 
resolution of a major gap in previous risk assessment tools.6 Nevertheless, estimating the 10-year mortality risk in people aged 
≥ 80 years of limited use. In Europe, especially in the south, life expectancy is increasing markedly. Therefore, it is necessary 
to start to pay more attention to CVD risk in the very elderly. It has been shown that people aged ≥ 80 years will benefit from 
preventive interventions, such as antihypertensive drug treatment if hypertensive.35 Further analysis to explore 5-year risk 
estimation will be done in the near future, based on the elderly people included in this project. Other investigators also have 
started to develop risk scores in elderly cohorts.7 
Limitations and Strengths 
The ERICE charts only consider the major CVD risk factors but, in practice, other factors (family history, high-density 
lipoprotein cholesterol, fibrinogen, physical exercise, waist circumference, etc.) can also modulate the CVD risk. People lost to 
follow-up were younger, and there were more smokers among female participants. No other significant differences in the 
distribution of risk factors were observed and thus the selection bias is minimal. High-density lipoprotein cholesterol 
measurement methods are different from one center to another, and this could have influenced the involvement of this factor in 
risk estimations. The Murcia cohort did not have data on blood glucose levels but information about drug treatment for DM 
was recorded. The predictive value of classical risk factors, such as hypercholesterolemia and systolic HT, weakens with 
age36 and 37, and absolute risk estimations in some cells, particularly in those groups of older adults with very high TC 
(> 7.8 mmol/L) and SBP, could be less accurate because of this fact and the lower number of individuals. 
The study has several strengths. The sample size was large and recruited from different geographical areas of Spain 
(northern, central, and southern areas), and it covers a wide age range, including a large proportion of elderly people (> 3000, 
25.4% of the total sample) and also people with DM. Almost half of participants were under pharmacological risk factor 
management (antihypertensive or lipid lowering drugs) at baseline, representing the current situation of CVD risk factor 
treatment at the population level. The ERICE estimates the total CVD risk (CHD and stroke), and also includes DM as a risk 
factor along with age, smoking, SBP, and TC. The availability of information on cardiovascular risk factor treatment, 
particularly antihypertensive treatment, is another strength of this study, along with additional information useful for clinicians 
to adjust the estimated cardiovascular risk in those patients already under antihypertensive treatment. 
The pooled ERICE cohort provides a new prospective analysis on the association between total CVD and several risk 
factors in Spain, a European country with a low incidence of CVD. The ERICE score allows the direct estimation of total CVD 
risk in Spain based on the risk estimation in the Spanish population, rather than being based on foreign scores calibrated for the 
low-risk European population. Such extrapolations may vary widely when a risk estimation formula is applied to a different 
population, and may not work properly. 
Our results showed that the extent to which the effect of a specific risk factor, particularly TC, may need re-evaluation in 
the specific population to which it is going to be applied. It is expected that the internal validation of this risk score will be 
done in the near future. The external validation of the score in an independent Spanish cohort and the evaluation of its 
usefulness and impact compared with other existing scores, which deserved special attention in a recent issue of Revista 
Española de Cardiología, 38 and 39 are the next steps to approach. Finally, while this article was under review another function of 
global cardiovascular risk was published that included the population aged 35 to 79 years. 40 
Conclusions 
Age was the strongest risk factor for CVD in both sexes, as was well known. In our study, high SBP was the strongest 
modifiable risk factor of CVD in men, followed by DM and smoking. In women, DM played a crucial role, followed by high 
SBP and smoking. The contribution of TC to the CVD risk was small in the Spanish population, and in both sexes when 
considering all age groups in this study. The ERICE offers a new CVD risk estimation system for the Spanish population 
derived, from the local and contemporary CVD risk factor assessment comprising several local cohort studies from different 
parts of the country. The ERICE score offers a direct estimation of the total CVD risk rather than specific outcomes such as 
CHD only, and highlights the importance of considering existing drug treatment for high cardiovascular risk factors, inclusion 
of elderly people and the diabetic status in the risk estimation. The ERICE score is a new, practical tool for clinicians in Spain 
to estimate the total CVD in their patients. 
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